GI CANCERS

Lung Cancer

Selective internal radiation therapy with yttrium-90 resin microspheres was better tolerated compared with sorafenib in patients with advanced unresectable hepatocellular carcinoma, However, findings from the phase III SARAH trial did not improve rates of overall survival or progression-free survival. A radiotherapy approach was compared with this targeted therapy in the SARAH trial.

John Marshall, MD, recently discussed the treatment options and decisions he makes when treating patients with metastatic colorectal cancer. Marshall explained his treatment decisions based on 2 case scenarios during a <em>Targeted Oncology </em>live case-based peer perspectives presentation.

Edward M. Wolin, MD, has been named the director of the Center for Carcinoid and Neuroendocrine Tumors at The Tisch Cancer Institute of Mount Sinai Health System. He will also serve as a professor of medicine (hematology and medical oncology) at the Icahn School of Medicine at Mount Sinai.

Lung Cancer

According to results from the CALGB 8903 study published in the <em>Journal of Clinical Oncology, </em>there is an association between total nut intake and improved outcomes in patients with stage III colon cancer. Results of the study showed patients who ate at least 2 servings of nuts per week had superior disease-free survival and overall survival.

The FDA has granted a fast track designation to pamrevlumab for the treatment of patients with locally advanced, unresectable pancreatic cancer, according to FibroGen, the manufacturer of the first-in-class anti-CTGF antibody.

According to findings from the phase III REFLECT trial now published online in the <em>Lancet,</em>^&nbsp;lenvatinib improved progression-free survival and was noninferior for overall survival compared with sorafenib for the frontline treatment of patients with&nbsp;unresectable hepatocellular carcinoma.

Hackensack Meridian <em>Health</em> John Theurer Cancer Center at Hackensack University Medical Center has appointed Louis M. Weiner, MD, to its advisory board. Weiner is the director of the Georgetown Lombardi Cancer Center and director of the MedStar Georgetown Cancer Institute.

Michael A. Morse, MD, discusses a number of key trials that have broadened the treatment landscape of mCRC, the importance of toxicity management in this setting, and other ongoing developments in GI cancers.

Thomas Karasic, MD, investigator at Penn Medicine, discusses a phase II trial of palbociclib (Ibrance) in patients with advanced&nbsp;<br /> esophageal or gastric cancer.<br /> &nbsp;

Updated findings of the CheckMate-142 study presented by Michael J. Overman, MD, at the 2018 Gastrointestinal Cancers Symposium&nbsp;continued to support the use of nivolumab alone or in combination with ipilimumab for previously treated patients with DNA mismatch repair-deficient/microsatellite instability-high metastatic colorectal cancer.

NYU Langone Health&rsquo;s Perlmutter Cancer Center has announced that Paul E. Oberstein, MD, a nationally renowned clinician-scientist, will serve as director of Gastrointestinal (GI) Medical Oncology and assistant director of its recently established Pancreatic Cancer Center.